Navigation Links
AxoGen, Inc. Announces Changes to Board of Directors

Alachua, FL (PRWEB) August 25, 2014

AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported today that John McLaughlin, President and Chief Executive Officer of PDL BioPharma, Inc. has resigned from AxoGen’s Board of Directors.

Mr. McLaughlin joined AxoGen’s Board in 2012 as part of the Revenue Interest Purchase Agreement between AxoGen and PDL. At this time, PDL is not appointing a replacement for Mr. McLaughlin. As a result, the number of Directors has been reduced from eight to seven.

“It has been a great honor and pleasure to serve on the AxoGen Board. During the past two years, AxoGen has made great strides including 47% sales growth in the most recently reported quarter. AxoGen is an impressive company with medically important products that are of increasing commercial significance, an experienced management team whose execution is creating and will continue to create shareholder value, and a Board of Directors composed of knowledgeable and successful industry and healthcare veterans dedicated to the company’s success,” said Mr. McLaughlin. “I look forward to closely following the Company’s future development.”

AxoGen Board Chairman Jamie Grooms commented, “AxoGen continues to drive a paradigm change in the way surgical nerve repair is performed. During John’s tenure the Company has generated double digit growth and achieved many significant milestones. We would like to extend our sincere gratitude to John for his service to the Board, and his insights and leadership. In addition, we would like to thank PDL for its continued support of our development.”

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
2. AxoGen, Inc. Reports 47% Second Quarter Revenue Growth
3. AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
4. AxoGen, Inc. To Open New Distribution Facility in Burleson, TX
5. AxoGen, Inc. to Sponsor Surgeon Education Programs on Peripheral Nerve Surgery at American Society for Surgery of the Hand 2013
6. AxoGen, Inc. Announces Exercise of Over-Allotment Option
7. AxoGen, Inc. Closes $18 Million Offering and Moves to NASDAQ
8. AxoGen, Inc. Announces Pricing of $18 Million Underwritten Offering and Uplisting to NASDAQ
9. AxoGen, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
10. AxoGen, Inc. Reports Second Quarter 2013 Financial Results
11. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at the 18th Federation of European Societies for Surgery of the Hand Congress
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
Breaking Medicine Technology: